Non-Small Cell Lung Cancer

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-11-08

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

NSCLC comprises over 75% of all lung cancers. In 2006, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months.


Scope

  • Diagnosis patterns of NSCLC including stage distribution and extent of resectability based on a survey of 180 physicians across the seven markets
  • Analysis of treatment modalities and regimens according to Datamonitor’s primary research data
  • Ranking of the greatest areas of unmet need within the NSCLC market
  • Physician ratings of key pipeline NSCLC candidates and the likelihood of future scenarios occurring


    • Report Highlights
    According to Datamonitor’s research, one-third of all non-resectable advanced NSCLC patients receive no drug therapy. The development of agents suitable for elderly and poor performance status patients, inducing those with existing comorbidities, provides significant commercial opportunity

    While platinum-based regimens form the mainstay of first-line NSCLC treatment, Datamonitor’s research reveals that there is little to differentiate between the available cytotoxic regimens, indicating that the efficacy of cytotoxics may have reached a plateau.

    Avastin has become the first FDA approved MTT for the first-line treatment of NSCLC, labeled for administration in combination with carboplatin and paclitaxel. As more MTTs emerge from the developmental pipeline and targeted patient selection becomes more frequent, the treatment of NSCLC will undergo a transformation


    Reasons to Purchase

  • Identify the key factors that influence prescribing patterns for NSCLC pharmacotherapy
  • Examine the significant unmet needs in the NSCLC market and identify opportunities for new product development
  • Enhance your commercial positioning through an increased understanding of NSCLC market dynamics

    • Table of Contents

    Other users found this report page using the following search terms: non small cell lung cancer lung cancer nsclc lung cancer cell non small nsclc alimta avastin prognosis progression

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.